We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-4.06%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
-$13.8M
Cap. Flow
-$1.69M
Cap. Flow %
-1.33%
Top 10 Hldgs %
76.57%
Holding
60
New
3
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$638K
2
BLUE
bluebird bio
BLUE
+$578K
3
ELUT icon
Elutia
ELUT
+$536K
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$358K
5
PGNY icon
Progyny
PGNY
+$297K

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$2.53M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.5M
3
ATEC icon
Alphatec Holdings
ATEC
+$141K
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$117K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$102K

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Energy 3.59%
3 Consumer Staples 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETRN
26
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$769K 0.6%
133,050
– –
TVTX icon
27
Travere Therapeutics
TVTX
$5.33B
$675K 0.53%
+30,000
New +$638K
BLUE
28
DELISTED
bluebird bio
BLUE
$633K 0.5%
9,960
+5,060
+103% +$578K
TSVT
29
DELISTED
2seventy bio
TSVT
$610K 0.48%
59,833
– –
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$608K 0.48%
25,000
– –
IMGN
31
DELISTED
Immunogen Inc
IMGN
$576K 0.45%
150,000
– –
TXG icon
32
10x Genomics
TXG
$5.87B
$558K 0.44%
10,000
– –
SLNO
33
DELISTED
Soleno Therapeutics
SLNO
$525K 0.41%
245,127
– –
ARVN icon
34
Arvinas
ARVN
$518M
$410K 0.32%
15,000
– –
SILK
35
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$391K 0.31%
10,000
– –
HALO icon
36
Halozyme
HALO
$9.72B
$382K 0.3%
10,000
– –
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.32B
$358K 0.28%
10,000
– –
KDNY
38
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$347K 0.27%
+15,000
New +$358K
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.66B
$345K 0.27%
2,500
– –
XNCR icon
40
Xencor
XNCR
$1.44B
$343K 0.27%
12,300
– –
KNSA icon
41
Kiniksa Pharmaceuticals
KNSA
$4.83B
$323K 0.25%
30,000
– –
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$314K 0.25%
40,000
– –
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$311K 0.24%
28,000
– –
KROS icon
44
Keros Therapeutics
KROS
$199M
$299K 0.23%
7,000
– –
PGNY icon
45
Progyny
PGNY
$2.44B
$289K 0.23%
+9,000
New +$297K
CGEM icon
46
Cullinan Oncology
CGEM
$1.05B
$257K 0.2%
25,114
– –
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.37B
$167K 0.13%
20,000
– –
IFRX icon
48
InflaRx
IFRX
$256M
$136K 0.11%
70,000
– –
GOSS icon
49
Gossamer Bio
GOSS
$66.5M
$125K 0.1%
99,088
– –
STOK icon
50
Stoke Therapeutics
STOK
$1.82B
$125K 0.1%
15,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Birchview Capital held 60 positions worth $128M, down 9.8% from $142M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Birchview Capital's Q1 2023 filing shows 3 new, 5 increased, 1 reduced and 5 closed positions. Its largest new stake was Travere Therapeutics: 30,000 shares worth $675K. The largest sale was Albireo Pharma Inc, an estimated $2.53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2023 buy was Travere Therapeutics: 30,000 shares worth $675K.
  • Birchview Capital added most to bluebird bio in Q1 2023, an estimated $578K increase.
  • Birchview Capital's biggest Q1 2023 reduction was Alphatec Holdings, cutting an estimated $141K.
  • Birchview Capital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.53M.
  • Birchview Capital's ten largest holdings make up 77% of its $128M portfolio in Q1 2023.
  • Birchview Capital opened 3 new positions and closed 5 in Q1 2023.
  • Birchview Capital's portfolio value fell 9.8% quarter-over-quarter to $128M.

Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.